Rob Aarnoutse, PharmD PhD, is Associate Professor, hospital pharmacist and clinical pharmacologist, working at the Department of Pharmacy and with the Radboud Institute for Health Sciences at Radboudumc.
His research is focused on drug treatment of tuberculosis (TB), HIV and TB/HIV co-infection, the leading infectious disease killers worldwide. The central concept in his work is that efficacy and toxicity of drugs are dependent on drug concentrations achieved either systemically or locally. His research portfolio reaches from molecular pharmacological research to murine pharmacological studies, to pharmacokinetic studies in humans and clinical trials. In this way he develops a comprehensive translational research line that allows for quick application of relevant findings in the clinical setting. Typical topics of interest are adherence, pharmacokinetics, pharmacodynamics, safety/tolerability and effectiveness of TB drugs, antiretrovirals, other anti-infective drugs and immunosuppressants. His research is performed in The Netherlands, Indonesia, Tanzania, South Africa and other countries.
Rob Aarnoutse headed the Pharmacokinetic & Therapeutic Drug Monitoring Laboratory at Radboudumc for several years, is deputy director of education in hospital pharmacy for Radboudumc and is member of the Ethical Review Board Arnhem/Nijmegen. He has been active in various national boards for the Dutch Society of Hospital Pharmacists (NVZA) and for SKML. He is member of the Coordinating and Executive Group of the Pan African Consortium for the Evaluation of Antituberculosis Antibiotics (PanACEA), is the chairman of the annual International Workshop on Clinical Pharmacology of Tuberculosis Drugs, and is otherwise well embedded in national and international gremia relevant to translational pharmacological research in the field of infectious diseases.
Dr. Francis Mhimbira is an epidemiologist and a TB clinical research scientist at Ifakara Health Institute (IHI, www.ihi.or.tz). He is the head of Interventions and Clinical Trials department at IHI. He has worked at Kibong’oto National TB Hospital in Tanzania (2006-2011) where he gained clinical experience on managing TB and TB/HIV co-infected patients. He joined IHI (2012-to date) and has been working in the TB research as a clinical research coordinator and investigator in a number of clinical trials, TB diagnostic studies and epidemiological studies on TB and co-infections in particular HIV and helminth infections. He was the site investigator for HIGH-RIF, NC-002, NC-005 and STAND TB drugs clinical trials. He also works with the Tanzania National TB and Leprosy Programme as a technical advisor to the TB Operational Research and Programmatic Management of Drug Resistant Tuberculosis Technical Working Groups.
Dr. Francis received his medical degree from University of Dar es Salaam, Tanzania, a Masters’ degree in Epidemiology from University of Melbourne, Australia and a PhD in Epidemiology from University of Basel, Switzerland.
Elin Svensson is a postdoctoral researcher at Radboud university medical center, focusing on pharmacokinetic and pharmacodynamic population modeling of clinical trial data. Elin holds a MSc in chemical engineering, and a PhD in pharmacometrics, both from Uppsala University, Sweden. The topic of her doctoral thesis was modeling of drug-drug interactions and exposure-response relationships for novel anti-tuberculosis drugs, partly within the PreDiCT-TB consortium. Elin also maintains a part-time researcher position at Uppsala University, and a close collaboration with the University of Cape Town, South Africa. She is part of several study protocol teams within the IMPAACT network, and is a member of the WHO Task force on PK/PD of tuberculosis medicines. Elin’s role in PanACEA includes study design and data analysis, primarily addressing questions regarding exposure-response relationships, dose optimization and biomarkers.
Olinde is a research assistant in the PanACEA coordinating team at the Radboud University Medical Centre in Nijmegen, the Netherlands. She is responsible for the PanACEA secretariat and communication. She supports the management team with consortium and trial coordination. Olinde has a BA in Cultural Anthropology and Development studies and is currently finishing the master Political Theory, a specialization in Political Science at the Radboud University. Before her activities in PanACEA Olinde gained experience in study related boards and committees, services and administration.
In 2006 Rutger completed his studies in Business Administration at the Radboud University in Nijmegen, and graduated with majors in Strategic Human Resource Management. In 2006 he started working at PwC accountants as financial auditor mainly for SME’s and in Healthcare. At the same time he started his study in Auditing at the Vrije University in Amsterdam. In 2009 he started working for the Radboud University Medical Center as Senior Projectcontroller and Teamleader for the department of Finance. He helped Principal Investigators and researchers at various departments managing their projects. In this role he started in 2012 supporting the PanACEA I project. He helped with budgeting, financial reporting and auditing the financial reports from partners. In March 2017 he started working as project manager on PanACEA-II, focusing on consortium coordination, legal en financial.
In 2012 Lindsey completed her studies in Biomedical sciences at the Radboud University in Nijmegen, and graduated with majors in Occupational and Environmental Health and in Toxicology. In august 2012 she started her PhD at the Radboud university medical center, in which she studied the molecular mechanisms underlying (un)wanted transporter mediated drug-drug interactions and assessed the pharmacokinetics and drug-related adverse events of TB drugs as part of multiple drug therapy in TB patients. For the pharmacokinetic studies she spent considerable time at Universitas Padjadjaran and Hasan Sadikin hospital in Bandung, Indonesia, an important partner in tuberculosis research for the Radboudumc. During her PhD Lindsey also completed the training required for the register of professional toxicologists by the Netherlands Society of Toxicology (NVT). After finishing her PhD, in January 2017, Lindsey is continuing her work as a postdoctoral researcher, studying potential new and safe drug regimens against tuberculous meningitis. Furthermore starting from March 2017, she is working as project manager on PanACEA-II, focusing on HIGHRIF1, trial and consortium coordination, drug management, pharmacology, and providing scientific support.
Claudia Scheiber works as a project manager at the Department for Infectious Diseases & Tropical Medicine at the Medical Center of the Ludwig-Maximilians-University, Munich. She graduated in Biology at the University of Cologne, Germany, and studied Public Health at the London School of Hygiëne and Tropical Medicine with a focus on communicable disease control. Having worked as a clinical project manager in the pharmaceutical industry for over 10 years she has experience in the management of international clinical trials.
Sarah Konsten works as sponsor clinician at the Department for Infectious Diseases & Tropical Medicine at the Medical Center of the Ludwig-Maximilians-Universität, Munich. She studied Medicine at the University of Maastricht, in the Netherlands and completed a Master´s degree in Global Health at this same University, thereafter. She has experience working as an intern in several developing countries and has practiced medicine in the fields of internal medicine and neurology.
Nilesh Bhatt is a project investigator on PanACEA II and oversees implementation of project related activities in Mozambique. Since 2011, Dr Bhatt is the Director General of the Polana Caniço Health Research and Training Center (CISPOC), a research of Instituto Nacional de Saúde (INS), at Mozambique’s Ministry of Health. Dr. Bhatt has been a researcher at the INS since 2007, where he also served as the Head of the Department of Immunology from 2009 to 2011.
Nilesh Bhatt qualified as a medical doctor at the Eduardo Mondlane University in Mozambique. He received a Master in Medicine (STD-HIV/AIDS) from the University of Sydney in the Australia and a Ph.D. in Health Science from the Fundação Oswaldo Cruz (FIOCRUZ) in the Brazil. During his career Dr. Bhatt has lead efforts in the area of clinical research with the objective of understanding the critical public health concerns in area of infectious diseases in Mozambique. His research interests include HIV and tuberculosis therapeutics and diagnostics, including the deployment of these health technologies in resource-limited health systems. Dr. Bhatt has authored over 10 publications in peer-reviewed scientific journals.
Dr. Bhatt is currently a member of the Institutional Bioethical Committee of INS and lecturer in the Faculty of Medicine of Eduardo Mondlane University, Mozambique.
Ilesh Jani is a project investigator at PanACEA II and oversees the project activities in Mozambique. Since 2009, he is the Director General of the Instituto Nacional de Saúde (INS) at Mozambique’s Ministry of Health. Dr. Jani has been a researcher at the INS since 1998, where he also served as the Head of the Department of Immunology from 2004 to 2009.
Ilesh Jani qualified as a medical doctor at the Eduardo Mondlane University in Mozambique. He received a Ph.D. in immunology from the University of London in the United Kingdom. During his career Dr. Jani has lead efforts in the areas of research, public health, education and diagnostics with the objective of strengthening the health system in Mozambique. His research interests include vaccines and diagnostics, including the deployment of these health technologies in resource-limited health systems. Dr. Jani has authored over 50 publications in peer-reviewed scientific journals.
Dr. Jani is currently a member of the executive board of the International Association of National Public Health Institutes (IANPHI), a member of WHO’s Strategic Advisory Group of Experts on Immunization (SAGE), and a member of the Program Committee of the Conference on Retroviruses and Opportunistic Infections (CROI).